30+ years across international pharmaceutical markets, combining corporate leadership, business building, strategic partnerships, market access and hands-on commercial execution.
I have spent more than 30 years in the pharmaceutical industry, working across international business development, market access, strategic partnerships, licensing, portfolio strategy and commercial execution.
My career combines senior corporate leadership and entrepreneurial business building across Novartis, Adamed Pharma, Exeltis / Temapharm and Egis Pharmaceuticals — spanning branded medicines, generics, value-added products and biotech — and today, independent advisory work through AceArtis.
Across these environments, I have worked on one recurring challenge: how to translate market potential into commercially viable portfolio choices, partnership models, market-entry strategies and sustainable international business.
I was appointed Managing Director at a critical stage in Adamed’s development and worked directly with the company’s owners on portfolio expansion, commercialisation, reimbursement and international growth. During this period, I contributed to the company’s development from around 30th position to a Top 10 pharmaceutical company in Poland.
I founded and built Temapharm from the ground up across portfolio strategy, licensing, IP, R&D, registration, market access and commercial launch. I built the company into a Top 10 player in Polish gynaecology, developed an IP strategy that created a period of generic market exclusivity, and expanded the business across Poland, the Czech Republic and Slovakia.
I led Egis’ international B2B business and strategic partnerships across B2B sales, out-licensing, API and CMO/CDMO activities. I built and led an international B2B organisation, strengthened strategic partnerships and expanded the company’s commercial footprint across multiple regions.
At Novartis Specialty Nutrition, I held senior commercial, marketing and business development responsibilities, including business unit marketing leadership and a period as Acting Business Unit Head, working across international markets within a global matrix organisation.
Entry barriers, reimbursement, regulatory realities and commercially viable market-entry models.
Portfolio building, product prioritisation, in-licensing, out-licensing and commercially viable partner models.
New clients, markets, strategic partnerships and cross-border commercial opportunities.
Partner selection, negotiation, governance and development of strategic commercial relationships.
Connecting strategic choices with implementation — negotiations, launch coordination and delivery.
Working across Commercial, Regulatory, Market Access, Medical, Manufacturing, Supply Chain and Finance.
Poland, Hungary, Czech Republic, Slovakia and neighbouring markets.
Ukraine, Russia and selected neighbouring markets.
Kazakhstan, Uzbekistan, Georgia, Armenia, Azerbaijan and selected markets in the region.
Selected Middle Eastern and Gulf markets.
Vietnam, the Philippines, Thailand, Indonesia, Singapore and other markets in the region.
China, South Korea, Japan and selected markets in the region.
Selected markets in Central and South America.
Spain, Portugal, Italy, Germany, France and other markets in the region.
I take direct responsibility for the projects I lead. When the scope requires broader expertise, I can involve trusted senior professionals from my network, bringing complementary experience across business development, market access, regulatory, commercial and related areas.
I also work with established local contacts in selected markets, which helps bring practical market insight, partner access and on-the-ground perspective into the project.
Clients therefore have one senior point of accountability, while benefiting from broader expertise and local market reach when needed.
I am open to conversations around international pharmaceutical business development, strategic partnerships, market entry, licensing, portfolio strategy and selected expansion opportunities — starting from the business situation rather than a predefined solution.
